)
In a filing to the BSE on Wednesday, the company said that the granted claims of the patents included the class of selective 5-HT compounds discovered by Suven and were being developed as therapeutic agents.
These therapeutic agents are useful in the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer's, attention deficient hyperactivity, Huntington's, Parkinson and Schizophrenia diseases, it added.
With these new patents, Suven now has 17 granted patents from the US, and products out of these inventions may be out-licensed at various phases of clinical development like at Phase-I or Phase-II, the company said.
Suven Life Sciences' scrip is currently trading at Rs 72.30 on the BSE, up 1.54%, over the previous close of Rs 71.20 a share.
